In the latest trading session, 1.35 million Turnstone Biologics Corp (NASDAQ:TSBX) shares changed hands as the company’s beta touched 2.04. With the company’s most recent per share price at $0.44 changing hands around $0.03 or 7.17% at last look, the market valuation stands at $10.13M. TSBX’s current price is a discount, trading about -1206.82% off its 52-week high of $5.75. The share price had its 52-week low at $0.40, which suggests the last value was 9.09% up since then. When we look at Turnstone Biologics Corp’s average trading volume, we note the 10-day average is 0.15 million shares, with the 3-month average coming to 274.55K.
Analysts gave the Turnstone Biologics Corp (TSBX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.50. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TSBX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Turnstone Biologics Corp’s EPS for the current quarter is expected to be -0.86.
Turnstone Biologics Corp (NASDAQ:TSBX) trade information
Instantly TSBX is in green as seen in intraday trades today. With action -3.99%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -11.87%, with the 5-day performance at -3.99% in the red. However, in the 30-day time frame, Turnstone Biologics Corp (NASDAQ:TSBX) is -18.53% down. Looking at the short shares, we see there were 0.47 million shares sold at short interest cover period of 3.24 days.
The consensus price target for the stock as assigned by Wall Street analysts is 0.5, meaning bulls need an upside of 12.0% from its recent market value. According to analyst projections, TSBX’s forecast low is 0.5 with 0.5 as the target high. To hit the forecast high, the stock’s price needs a -13.64% plunge from its current level, while the stock would need to soar -13.64% for it to hit the projected low.
Turnstone Biologics Corp (TSBX) estimates and forecasts
Data shows that the Turnstone Biologics Corp share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -81.60% over the past 6 months, a 29.29% in annual growth rate that is considerably higher than the industry average of 15.90%. Year-over-year growth is forecast to reach -100.00% down from the last financial year.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%. The 2025 estimates are for Turnstone Biologics Corp earnings to increase by 29.39%, but the outlook for the next 5-year period is at 1.99% per year.
Turnstone Biologics Corp (NASDAQ:TSBX)’s Major holders
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund. With 495.07 shares estimated at $0.22 million under it, the former controlled 2.14% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.37% of the shares, roughly 85.73 shares worth around $37721.0.
